Explore Other Treatments
Highlights
Nemolizumab significantly reduces itching (pruritus) in patients with moderate-to-severe atopic dermatitis. In clinical trials, patients saw 40-70% reduction in itch scores after 16 weeks of treatment, with improvements noticeable within the first few days.
| Study Summary | Study Type | Studied Population | Results |
|---|---|---|---|
|
š
Nemolizumab, when used with topical treatments, reduced itching by 43% compared to 21% with placebo after 16 weeks. The medication also improved eczema severity and sleep quality in Japanese patients with moderate-to-severe atopic dermatitis.
|
Clinical Trial |
Total Patients: 215
|
Nemolizumab reduced itching twice as much as placebo |
|
š
Nemolizumab, when used with topical treatments, significantly improved eczema symptoms and reduced itching in patients with moderate-to-severe atopic dermatitis. The medication showed benefits as early as week 1 for itch reduction, and by week 16, 36-38% of patients had clear or almost clear skin compared to 25-26% on placebo.
|
Clinical Trial |
Total Patients: 1,728
|
|
|
š
Nemolizumab, given as an injection every 4 weeks, significantly improved both skin inflammation and itch in patients with moderate-to-severe eczema. The 30mg dose worked best, with patients experiencing about 69% improvement in their eczema severity and 67% reduction in itch after 24 weeks.
|
Clinical Trial |
Total Patients: 226
Severity: moderate to severe Age: 18+
|
Nemolizumab, when used with topical treatments, reduced itching by 43% compared to 21% with placebo after 16 weeks. The medication also improved eczema severity and sleep quality in Japanese patients with moderate-to-severe atopic dermatitis.
Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus.Nemolizumab, when used with topical treatments, significantly improved eczema symptoms and reduced itching in patients with moderate-to-severe atopic dermatitis. The medication showed benefits as early as week 1 for itch reduction, and by week 16, 36-38% of patients had clear or almost clear skin compared to 25-26% on placebo.
Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trialsNemolizumab, given as an injection every 4 weeks, significantly improved both skin inflammation and itch in patients with moderate-to-severe eczema. The 30mg dose worked best, with patients experiencing about 69% improvement in their eczema severity and 67% reduction in itch after 24 weeks.
Phase 2b Randomized Study of Nemolizumab in Adults with Moderate-Severe Atopic Dermatitis and Severe Pruritus.The medication improves skin symptoms and quality of life, including better sleep. Studies showed 45-78% improvement in eczema severity scores over 16-68 weeks of treatment.
| Study Summary | Study Type | Studied Population | Results |
|---|---|---|---|
|
š
Nemolizumab, given as an injection every 4 weeks along with topical treatments, helped reduce itching by 66% and eczema severity by 78% over 68 weeks in patients with moderate-to-severe atopic dermatitis. The improvements lasted even after treatment ended, and the medication was generally safe to use.
|
Clinical Trial |
Total Patients: 303
Severity: moderate to severe Age: ā„13 years
|
Significant reduction in itching maintained over more than a year |
|
š
Nemolizumab, when used with topical treatments, significantly improved eczema symptoms and reduced itching in patients with moderate-to-severe atopic dermatitis. The medication showed benefits as early as week 1 for itch reduction, and by week 16, 36-38% of patients had clear or almost clear skin compared to 25-26% on placebo.
|
Clinical Trial |
Total Patients: 1,728
|
Nemolizumab, given as an injection every 4 weeks along with topical treatments, helped reduce itching by 66% and eczema severity by 78% over 68 weeks in patients with moderate-to-severe atopic dermatitis. The improvements lasted even after treatment ended, and the medication was generally safe to use.
Nemolizumab plus topical agents in patients with atopic dermatitis (AD) and moderateātoāsevere pruritus provide improvement in pruritus and signs of AD for up to 68 weeks: results from two phase III, longāterm studiesNemolizumab, when used with topical treatments, significantly improved eczema symptoms and reduced itching in patients with moderate-to-severe atopic dermatitis. The medication showed benefits as early as week 1 for itch reduction, and by week 16, 36-38% of patients had clear or almost clear skin compared to 25-26% on placebo.
Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trialsThe most common side effects are mild and include nasopharyngitis (common cold), upper respiratory tract infections, and worsening of atopic dermatitis. Serious side effects are rare but can include severe allergic reactions.
| Study Summary | Study Type | Studied Population | Results |
|---|---|---|---|
|
š
Nemolizumab, given as an injection every 4 weeks, significantly improved both skin inflammation and itch in patients with moderate-to-severe eczema. The 30mg dose worked best, with patients experiencing about 69% improvement in their eczema severity and 67% reduction in itch after 24 weeks.
|
Clinical Trial |
Total Patients: 226
Severity: moderate to severe Age: 18+
|
|
|
š
Nemolizumab is a new medication approved in Japan that helps reduce itching in patients with atopic dermatitis when other treatments haven't worked well enough. The medication is given as an injection every 4 weeks and showed improvements in both itching and skin symptoms for up to 68 weeks.
|
Review |
Severity: moderate to severe Age: 13+
|
Continuous improvement and/or maintenance of itching reduction up to 68 weeks |
Nemolizumab, given as an injection every 4 weeks, significantly improved both skin inflammation and itch in patients with moderate-to-severe eczema. The 30mg dose worked best, with patients experiencing about 69% improvement in their eczema severity and 67% reduction in itch after 24 weeks.
Phase 2b Randomized Study of Nemolizumab in Adults with Moderate-Severe Atopic Dermatitis and Severe Pruritus.Nemolizumab is a new medication approved in Japan that helps reduce itching in patients with atopic dermatitis when other treatments haven't worked well enough. The medication is given as an injection every 4 weeks and showed improvements in both itching and skin symptoms for up to 68 weeks.
[Pharmacological profiles and clinical findings of nemolizumab as treatment for pruritus associated with atopic dermatitis].The medication is given as a subcutaneous injection every 4 weeks. It works by blocking interleukin-31, a protein that triggers itching in atopic dermatitis.
| Study Summary | Study Type | Studied Population | Results |
|---|---|---|---|
|
š
Nemolizumab is a new medication approved in Japan that helps reduce itching in patients with atopic dermatitis when other treatments haven't worked well enough. The medication is given as an injection every 4 weeks and showed improvements in both itching and skin symptoms for up to 68 weeks.
|
Review |
Severity: moderate to severe Age: 13+
|
Continuous improvement and/or maintenance of itching reduction up to 68 weeks |
|
š
Nemolizumab is a new drug that targets IL-31, which is involved in causing eczema symptoms. The drug shows good results in reducing itch quickly and improving skin condition, with mostly mild side effects.
|
Review |
Severity: not available Age: not available
|
not available |
Nemolizumab is a new medication approved in Japan that helps reduce itching in patients with atopic dermatitis when other treatments haven't worked well enough. The medication is given as an injection every 4 weeks and showed improvements in both itching and skin symptoms for up to 68 weeks.
[Pharmacological profiles and clinical findings of nemolizumab as treatment for pruritus associated with atopic dermatitis].Nemolizumab is a new drug that targets IL-31, which is involved in causing eczema symptoms. The drug shows good results in reducing itch quickly and improving skin condition, with mostly mild side effects.
Nemolizumab for atopic dermatitis.Taken every 4 weeks
| Study Summary | Study Type | Studied Population | Results |
|---|
Itch relief in as soon as 48 hours
| Study Summary | Study Type | Studied Population | Results |
|---|
Unique mechanism of action
| Study Summary | Study Type | Studied Population | Results |
|---|
Is Nemluvio Right For Me?
-
You are an adult
-
You have prurigo nodularis (a chronic skin condition that causes intense itching and firm bumps on the skin)
Interested in eczema products?
As a member of the Lemma Health community, you'll stay up to date with research, hear about new products, and get exclusive access to discounts.
How Lemma Health Works
Discover effective treatments
Fill out a 3 minute questionnaire to find evidence-based treatments that work for you.
Meet your provider
Consult with a board-certified dermatologist. Discuss your treatment options and receive prescriptions.
Get treatment
Treatments are delivered to your door. Free of charge, of course.
Receive ongoing care
Your treatment team is available 7 days a week for questions, support, and guidance.
Ready?
Your journey with lemma health
Discover effective treatments with boardācertified dermatologists.
Get prescriptions for immediate relief.
Get your medications.
Design a plan for sustained relief with your personal care coordinator.
Experience less itch, reduced inflammation, better sleep, and improved wellbeing.
Review progress with your care team and fine-tune your plan.
Ensure that you have everything you need to maintain your relief.
Don't worry - your coordinator will remain available to you.
Enjoy 24/7/365 access to your dedicated care team.
Discover effective treatments with boardācertified dermatologists.
Get prescriptions for immediate relief.
Get your medications.
Design a plan for sustained relief with your personal care coordinator.
Experience less itch, reduced inflammation, better sleep, and improved wellbeing.
Enjoy 24/7/365 access to your dedicated care team.
Ensure that you have everything you need to maintain your relief.
Don't worry - your coordinator will remain available to you.
Review progress with your care team and fine-tune your plan.
Illustrative journey. Individual timelines and results may vary.
Ready for better skin health?
At Lemma Health, we provide evidence-based skin care. Access dermatologists in all 50 states - appointments available within 3 days. Receive your medications delivered. Message your dedicated care team 24/7/365.
Eczema is more than skin deep
Join our waitlist while we set up personalized holistic eczema care.
What are other patients saying?